GENE ONLINE|News &
Opinion
Blog

2021-09-22| Special

ESMO21: Latest Clinical Studies Answer Central Questions in the Treatment of Leading Cancers

by Sahana Shankar
Share To
Pfizer’s Sutent (Sunitinib) is an approved anti-cancer adjuvant, which works as a tyrosine kinase inhibitor, approved for many cancers such as renal cell carcinoma. Dr. Eric Baudin, Chairman at Gustave Roussy, France, presented data from a clinical trial that reworked Sunitinib as an adrenal cancer drug.

FIRSTMAPP was designed as the first randomized, double-blind, academic Phase 2 trial to evaluate the effectiveness of Sunitinib to treat malignant pheochromocytoma and paraganglioma (mPGGL)- a very rare subtype of adrenal cancer. Compared against the placebo arm, Sunitinib performed well in progression free survival, overall survival, and partial responses, with manageable adverse events and an acceptable safety profile. 

Discussing the success of Sunitinib as a potential therapy for mPPGL, Dr. Rocio Garcia Carbonero, from the Gastrointestinal Tumor Unit at the Hospital Universitario Doce de Octubre in Madrid, mentioned the requirement of a robust treatment for this very rare cancer. She made a case for angiogenesis inhibitors as an effective intervention for mPGGL since most patients have germline mutations in the developmental pathway required for angiogenesis and hypoxia sensing.

GO Prime with only $1.49 now

LATEST
Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19
2022-07-05
Breakthrough Zebrafish Genome Database Now Available
2022-07-05
WuXi Biologics Adds Microbial Fermentation to CDMO Offering in Hangzhou
2022-07-05
Sanofi Launches Nonprofit Brand To Distribute Medicines to Low-Income Countries
2022-07-05
As Private Equity Sale Becomes Less Likely, Novartis May Gravitate Towards Sandoz Spinoff
2022-07-04
Ascletis Begins Study of PD-L1 Antibody Candidate Against HIV
2022-07-04
Akebia Therapeutics Gains $55M Following Deal Termination by Otsuka Pharmaceutical
2022-07-04
EVENT
2022-07-27
BIO Asia–Taiwan 2022
Online and on-side
2022-08-03
BIOPLUS-INTERPHEX KOREA
Seoul
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-21
RESI Boston
Boston
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top